Posts in tag

new listings


The Generic and Biosimilar Medicines Association has welcomed the approval of biosimilar infliximab, Inflectra. Inflectra is the first biosimilar infliximab to be approved in Australia, providing an alternative, affordable treatment …

A government subsidy for a biologic to treat vision impairment caused by macular oedema in patients with diabetes or retinal vein occlusion (branch or central) will be available from 1 July.

MSD has welcomed the Federal Government’s announcement that patients with the most deadly form of skin cancer – advanced melanoma – will be able to access the company’s anti-PD1 immunotherapy …

The TGA has approved a new hepatitis C treatment, Gilead Sciences, Australia New Zealand, today announced.

Medicines Australia has expressed concerns about the proposed cuts to the PBS in tomorrow’s Budget. Health Minister, Sussan Ley’s announcement of the listing of new medicines and vaccines on the …

Macular Disease Foundation Australia today applauded the Federal Government’s decision to place the registered drug ranibizumab (Lucentis) on the PBS, enabling patients affordable access to this sight saving treatment for …

The Generic Medicines Industry Association has welcomed the PBAC’s decision to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the PBS. Basaglar is the first biosimilar …